The Royal Osteoporosis Society has set up an academy to ultimately to find a cure for osteoporosis.
News
New asthma pill to target airway muscles
Researchers are developing a new asthma pill Fevipiprant to target airway muscles to decrease attacks, potentially offering the first new oral treatment for asthma in 20 years.
What does it take to win a PharmaTimes award?
Earlier this month an event in London – ‘Behind the judging: An exclusive insight into all the major healthcare awards’ – offered a peek into the world of winning a coveted healthcare award.
Oncology sales drive AstraZeneca’s Q4 Earnings
AstraZeneca’s published Q4 earnings have shown better than expected results, with new launches and commercial execution delivering full-year sales growth and a very strong final quarter.
NICE provides first scientific advice on patient preference study design
The NICE Scientific Advice team, working with the Science Policy and Research team at NICE, has provided its first piece of advice on the design of a patient preference study.
AbCellera collaborates with Novartis for antibody discovery
AbCellera has announced a multi-target, multi-year deal with Novartis, to identify antibodies for ten therapeutic targets in Novartis’ pipeline, using a unique combination of microfluidics, high-throughput imaging, genomics, deep computing and AI.
Johnson & Johnson, Takeda and Evotec join The Dementia Consortium
The Dementia Consortium has expanded to include Johnson & Johnson Innovation, Takeda and Evotec, who join the unique £9.5 million charity-industry dementia drug discovery collaboration.
First patient dosed in ADCT-402 Phase I trial for lymphoma
ADC Therapeutics has announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumour activity of ADCT-402 in combination with AstraZeneca’s Imfinzi in patients with advanced diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma.
Could sound and vision be the future of drug discovery?
New research led by the University of St Andrews has claimed that a marriage of sound and light could hold the key to diagnosis of the early stages of various diseases, including cancer.
Spravato gets FDA Advisory Committee approval
FDA advisory committees have jointly voted in favour of approving Janssen’s Spravato nasal spray CIII for adults living with treatment-resistant depression.
Althea to launch cannabis based products in the UK
Althea, the Australian medicinal cannabis company, has launched in the UK, following changes allowing specialist doctors to prescribe cannabis-based products for medicinal use to certain patients.
Xtandi successful in prostate cancer Phase III trial
Pfizer and Astellas have unveiled results from the Phase III ARCHES trial in men with metastatic hormone-sensitive prostate cancer (HSPC), showing that Xtandi significantly improved radiographic progression-free survival, paving the way for an application to expand the drug’s use.
Bavencio combo gets FDA priority review for kidney cancer
The US Food and Drug Administration has accepted for priority review a supplemental Biologics License Application for Merck’s Bavencio (avelumab) in combination with Inlyta (axitinib) for patients with advanced renal cell carcinoma (RCC).
£2m available to revolutionise UK patient care
The Peter Sowerby Foundation has issued an open call to source a suitable project for up to £2 million of funding as part of the Foundation’s Health Breakthrough funding strand.
New NICE guidelines on antibiotic prescribing for pneumonia
The National Institute for Health and Care Excellence (NICE) and Public Health England (PHE) have published draft guidance on antimicrobial prescribing for hospital-acquired and community-acquired pneumonia, setting out a strategy designed to optimise antibiotic use and reduce antibiotic resistance.
